Pfizer signs Enodia Therapeutics deal on Sec61 small-molecule drugs

Pfizer

Pfizer has signed a research collaboration and license agreement with Enodia Therapeutics to discover and develop small-molecule Sec61 inhibitors. Enodia runs the discovery work against several collaboration targets; after the collaboration term, Pfizer takes over clinical, manufacturing, regulatory and commercial work.

• Enodia receives an upfront payment, amount not disclosed, plus research, development and sales milestones and tiered royalties on net sales; none of these amounts were disclosed.
• The announcement states a total potential value of more than $500 million.
• Enodia's approach is selective Sec61 translocon modulation, aiming to stop disease-driving proteins at the point of synthesis.
• Enodia says its platform spans several Sec61 inhibitor families and uses proteomics, cryo-EM and machine learning in molecule design.